Tamoxifen: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Tamoxifen |FDA_approval=Yes (for breast cancer treatment) |used_for=Investigational use in glioblastoma (GBM) treatment |clinical_trial_phase=Phase II clinical trials and retrospective studies |common_side_effects=Increased risk of blood clots, uterine cancer in women, impotence, and loss of libido in men, weight gain |OS_without=Not specified |OS_with=Varies; in gliomas, doses range from 160-240 mg per day showed tumor regression in 25% of pat...") |
No edit summary |
||
| Line 2: | Line 2: | ||
|drug_name=Tamoxifen | |drug_name=Tamoxifen | ||
|FDA_approval=Yes (for breast cancer treatment) | |FDA_approval=Yes (for breast cancer treatment) | ||
|used_for=Investigational use in glioblastoma (GBM) | |used_for=Investigational use in glioblastoma (GBM) due to its inhibition of protein kinase C | ||
|clinical_trial_phase=Phase II clinical trials and retrospective studies | |clinical_trial_phase=Phase II clinical trials and retrospective studies for GBM | ||
|common_side_effects= | |common_side_effects=Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain | ||
|OS_with=Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics | |||
|OS_with= | |PFS_with=In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens | ||
|PFS_with= | |||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes= | |notes=While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups. | ||
|category=Repurposed Drugs | |category=Repurposed Drugs | ||
|links= | |links= | ||
}} | }} | ||
Revision as of 08:53, 19 March 2024
| Property | Information |
|---|---|
| Drug Name | Tamoxifen |
| FDA Approval | Yes (for breast cancer treatment) |
| Used for | Investigational use in glioblastoma (GBM) due to its inhibition of protein kinase C |
| Clinical Trial Phase | Phase II clinical trials and retrospective studies for GBM |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain |
| OS without | Not specified |
| OS with | Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics |
| PFS without | Not specified |
| PFS with | In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.
From Ben Williams Book: Not specified
Loading comments...
